ABO(H) blood groups and vascular disease: A systematic review and meta-analysis

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 1, 2008, Pages 62-69

  Wu, O ^a   Bayoumi, N ^b   Vickers, M A ^b   Clark, Peter ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

ABO(H) blood groups; CIAO; MI; PVD; VTE

Indexed keywords

VON WILLEBRAND FACTOR;

ANGINA PECTORIS; ANTIGEN EXPRESSION; BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP O; BLOOD GROUP TYPING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

ABO BLOOD-GROUP SYSTEM; ANGINA PECTORIS; BRAIN ISCHEMIA; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; RISK; THROMBOSIS; VASCULAR DISEASES; VON WILLEBRAND FACTOR;

EID: 37549068918     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02818.x     Document Type: Review

References (80)

1. Jenkins P, O'Donnell J. ABO blood group determines plasma von Willebrand factor levels: A biological function after all. Transfusion 2006; 46: 1836-44.
2. Clark P, Sattar N, Walker ID, Greer IA. The Glasgow Outcome, APCR and Lipid (GOAL) Pregnancy Study: Significance of pregnancy associated activated protein C resistance. Thromb Haemost 2001; 85: 30-5.
3. Oliver M, Cumming R, Geigerova H. Serum cholesterol and ABO and Rhesus blood groups. Lancet 1969; II: 605.
4. Colonia V, Roisenberg I. Investigation of Associations between ABO blood groups and coagulation, fibrinolysis, total lipids, cholesterol and triglycerides. Hum Genet 1979; 48: 221-30.
5. Stormorken H, Erikssen J. Plasma antithrombin III and factor VIII antigen in relation to angiographic findings, angina and blood groups in middle-aged men. Thromb Haemost 1977; 38: 874-80.
6. Rodeghiero F, Tosetto A. The VITA Project: Population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen-relationship with physiological variables and establishment of reference ranges. Thromb Haemost 1996; 76: 226-33.
7. Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001; 41: 56-6.
8. Kmet L, Lee R, Cook L. Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields. Edmonton: Alberta Heritage Foundation for Medical Research; HTA Initiative #13, 2004.
9. NHS Centres for Review and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying out or Commissioning Reviews. 2nd edn. York: University of York; 2001.
10. Stroup D, Berlin J, Morton S. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Jama 2000; 283: 2008-12.
11. DerSimonian R, Laird N. meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
12. Daniels G. ABO, Hh and Lewis systems. Human Blood Groups. Oxford: Blackwell Science Ltd; 2002. 7-98.
13. Morelli V, de Visser M, Vos H, Bertina R, Rosendaal F. ABO blood group genotypes and the risk of venous thrombosis: Effect of factor V Leiden. J Thromb Haemost 2005; 3: 183-5.
14. Higgins J, Thompson S, Deeks JJ, Altman D. Measuring inconsistency in meta-analysis. Br Med J 2003; 327: 557-60.
15. van Houwelingen H, Arends L, Stijnen T. Advanced methods in meta-analysis: Multivariate approach and meta-regression. Statistical Medicine 2002; 21: 589-624.
16. Stern J, Egger M, Davey-Smith G. Investigating and dealing with publication and other biasis in meta-analysis. Br Med J 2001; 323: 101-5.
17. Viskum K, Astvad K, Fabricius-Bjerre N. Blood groups and acute myocardial infarction. Dan Med Bull 1975; 22: 126-8.
18. Platt D, Muhlberg W, Keiehl L, Schmitt-Ruth R. ABO blood group system, age, sex, risk factors and cardiac infarction. Arch Gerontol Geriat 1985; 4: 241-9.
19. Pell S, D'Alonzo C. A three year study of myocardial infarction in a large population. J Am Med Assoc 1961; 175: 463.
20. Medalie J, Levene C, Papier C, Goldbourt U, Dreyfuss F, Oron D. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. N Engl J Med 1971; 285: 1348-53.
21. Garrison R, Havlik R, Harris R, Feinleib M, Kannel W, Padgett S. ABO blood group and cardiovascular disease. Atheroscler 1976; 25: 311-8.
22. Denborough M. Blood groups and ischaemic heart disease. Br Med J 1962; II: 927.
23. Nefzger M, Hrubec Z, Chalmers T. Venous thromboembolism and blood group. Lancet 1969; I: 887.
24. Saha N, Toh C, Ghosh M. Genetic association in myocardial infarction. Ethnicity, ABO, Rh, Le (a), Xg (a) Blood groups, G6PD deficiency and abnormal haemoglobins. J Med Genet 1973; 10: 340-5.
25. Srivastava B, Thakur C, Das M. ABO blood groups in relation to ischaemic heart disease. J Indian Med Assoc 1966; 47: 261-2.
26. Maurer R, Hickey N, Mulcahy R. ABO and Rh blood groups in patients with coronary heart disease. Irish Journal of Medical Science 7th series 1969; 2: 105-8.
27. van Hoote O, Kesteloot H. An epidemiological survey of risk factors for ischaemic heart disease in 42,804 men. 1. -serum cholesterol value. Acta Cardiol 1972; 27: 527-64.
28. Oliver M, Cumming R. Blood groups and heart disease. Br Med J 1962; II: 51.
29. Jick H, Dinan B, Herman R, Rothman KJ. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors. Jama 1978; 240: 2548-52.
30. Whincup P, Cook D, Phillips A, Shaper A. ABO blood groups and ischaemic heart disease in british men. Br Med J 1990; 300: 1679-82.
31. Erikssen J, Thaulow E, Stormorken H, Brendemoen O, Hellem A. ABO blood groups and coronary artery disease (CHD): A study in subjects with severe and latent CHD. Thromb Haemost 1980; 43: 137-40.
32. Bronte-Stewart B, Botha M, Krut L. ABO blood groups in relation to ischaemic heart disease. Br Med J 1962; I: 1646-50.
33. Allan TM, Dawson AA. ABO blood groups and ischaemic heart disease in men. Br Heart J 1968; 30: 377-82.
34. Weiss N. ABO blood type and arteriosclerosis obliterans. Am J Hum Genet 1972; 24: 65-70.
35. Blann A, Seigneur M, Steiner M, Boiddeau M, McCollum C. Circulating endothelial cell markers in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27: 916-21.
36. Cronenwett J, Davis J, Edward Garrett H. ABO blood group and serum lipids in female atherosclerosis. J Cardiovasc Surg 1983; 24: 658-61.
37. Hall R, Bunch G, Humphrey C. The frequencies of ABO blood groups and secretors of ABH substances in peripheral atherosclerosis. Atheroscler 1971; 14: 241-6.
38. MacAndrew R. Venous thrombo-embolism and blood group. Lancet 1969; I: 1263.
39. Kingsbury K. Relation of ABO blood groups to atherosclerosis. Lancet 1971; I: 199-203.
40. Norrgard O, Beckman G, Cedergren B. HLA antigens, blood groups and serum protein groups in patients with intermittent claudication. Hum Heredity 1989; 39: 192-5.
41. Sostaric V, Bozicevi D, Brinar V, Grbavac Z. Hereditary antigen characteristics of blood in ischemic cerebrovascular accident. Neurologia Croatica 1991; 40: 3-11.
42. Ionescu DA, Marcu I, Bicescu E. Cerebral thrombosis, cerebral haemorrhage, and ABO blood-groups. Lancet 1976; 1: 278-80.
43. Herman B, Schmitz PI, Leyten AC, Van LJH, Frenken CW, Op De Coul AA, Schulte BP. Multivariate logistic analysis of risk factors for stroke in Tilburg, The Netherlands. Am J Epidemiol 1983; 118: 514-25.
44. Schleef M, Erwin S, Dick A, Frank J, Schramm W, Spannagl M. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005; 128: 100-7.
45. Carter YM, Caps MT, Meissner MH. Deep venous thrombosis and ABO blood group are unrelated in trauma patients. J Traum Injury Infection & Critical Care 2002; 52: 112-6.
46. Robert A, Aillaud MF, Eschwege V, Randrianjohany A, Scarabin Y, Juhan-Vague I. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemost 2000; 83: 630-1.
47. Gonzalez OAJ, Medina RJM, Martin L, Alvarez V, Coto E. The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coag Fibrinol 1999; 10: 303-7.
48. Wautrecht JC, Galle C, Motte S, Dereume JP, Dramaix M. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost 1998; 79: 688-9.
49. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Internal Med 1992; 232: 155-60.
50. Robinson WM, Roisenberg I. Venous thromboembolism and ABO blood groups in a Brazilian population. Hum Genet 1980; 55: 129-31.
51. Talbot S, Wakley E, Langman M. A1, A2, B and O blood groups, Lewis blood groups and serum triglyceride and cholesterol concentrations in patients with venous thrombo-embolic disease. Lancet 1972; I: 1152-4.
52. Arthes F. An epidemiologic survey of hospitalised cases of venous thrombosis and pulmonary embolism in young women. Millabnd Mem Fund Q 1972; 50(Suppl. 2): 233-43.
53. Talbot S, Wakley E, Ryrie D, Langman M. ABO blood groups and venous thromboembolic disease. Lancet 1970; I: 1257-9.
54. Jick H, Slone D, Westerholm B, Inman WH, Vessey MP, Shapiro S, Lewis GP, Worcester J. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1969; 1: 539-42.
55. Westerholm B, Wiechel B, Eklund G. Oral contraceptives, venous thromboembolic disease and ABO blood type. Lancet 1971; II: 664.
56. Dick W, Schneider W, Brockmuller K, Mayer W. Interrelations of thrombo-embolic diseases and blood group distribution. Thromb Diath Haemorrh 1963; 9: 472-4.
57. Johnson R, Green J, Charnley J. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement. Clin Orthop 1977; 127: 123-32.
58. Mercier B, Oger E, Le Gal G, Mottier D, Ferec C. Phenotypic but not allelic ABO blood group association with risk of venous thrombosis. Thromb Haemos 2005; 93: 388-9.
59. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal FR. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006; 77: 67-73.
60. Suadicani P, Hein HO, Gyntelberg F. Socioeconomic status, ABO phenotypes and risk ischaemic heart disease: An 8year follow-up in the Copenhagen Male study. J Cardiovasc Risk 2000; 7: 277-83.
61. Ohira T, Cushman M, Tsai M, Zhang Y, Heckbert S, Zakai N, Rosamond WD, Folsom AR. ABO blood group, other risk factors and incidence of venous thromboembolism: The longitudinal investigation of Thromboembolism Etiology (LITE). J Thromb Haemost 2007; 5: 1455-61.
62. Larsen S, Anthonisen B, Marquardsen J. Cerebral infarction, cerebral haemorrhage, and ABO blood-groups. Lancet 1977; 1: 1064.
63. Tirado I, Mateo J, Soria J, Oliver A, Martinez-Sanchez E, Vallve C, Borrell M, Urrutia T, Fontcuberta J. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism. Thromb Haemost 2005; 93: 468-74.
64. Vormittag R, Bencur P, Ay C, Tengler T, Vukovich T, Quehenberger P, Mannhalter C, Pabinger I. Low-density lipoprotein receptor-related protein 1 polymorphism 633 C>T affects clotting factor VIII activity and increases the risk of venous thromboembolism. J Thromb Haemost 2007; 5: 497-502.
65. Larsen T, Johnsen S, Gislum M, Moller A, Larsen H, Sorensen H. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. J Thromb Haemost 2005; 3: 300-4.
66. Procare-GEHT group. ABO blood group but not haemostatic genetic polymorphisms significantly influence the thrombotic risk: A study of 180 homozygotes for the Factor V leiden mutation. Br J Haematol 2006; 135: 697-702.
67. Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
68. Meade T, Cooper J, Stirling Y. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994; 88: 601-7.
69. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
70. Nossent AY, van Marion V, van Tilburg NH, Rosendaal FR, Bertina RM, van Mourik JA, Eikenboom HCJ. von Willebrand factor and its propeptide: The influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006; 4: 2556-62.
71. Folsom A, Wu K, Rosamond W, Sharrat A, Chambles L. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 1102-8.
72. Blann A, Miller J, McCollum C. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atheroscler 1997; 132: 151-6.
73. Ruggeri Z, Dent J, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999; 94: 172-8.
74. Danesh J, Wheeler J, Hirschfield G, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-97.
75. Smith E, Lowe G, Lee A, Rumley A, Leng G, Fowkes F. Smoking, hemorheologic factors and progression of peripheral arterial disease in patients with claudication. J Vasc Surg 1998; 28: 129-35.
76. O'Donnell J, Laffan M. The relationship between ABO histo-blood group, factor VIII and von-Willebrand factor. Transfusion Med 2001; 11: 343-51.
77. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P. von Willebrand factor and coronary artery disease. Eur Heart J 2002; 23: 1764-70.
78. Ikin E, Prior A, Race R, Taylor G. The distribution of A1A2BO blood groups in England. Ann Eugen 1939; 9: 409-11.
79. Walker I, Greaves M, Preston A. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512-28.
80. Clark P, Twaddle S, Walker I, Scott L, Greer I. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002; 359: 1919-20.